细胞因子诱导的杀伤细胞免疫治疗对非小细胞肺癌患者术后免疫功能的影响

Effect of Cytokine-induced Killer Cells Immunotherapy on Immunity Function of Non-small Cell Lung Cancer Patients after Operation

目的探讨细胞因子诱导的杀伤(CIK)细胞免疫治疗对术后非小细胞肺癌(NSCLC)患者免疫功能的影响。方法选取期、期和a期NSCLC患者50例,经手术治疗后随机分为两组,常规治疗组和CIK细胞治疗组,每组25例;分别于治疗前、治疗后2周、4周和8周动态监测患者免疫功能指标,包括外周血CD3+、CD4+、CD4+/CD8+比值、NK细胞比率以及Th1/Th2细胞因子水平。结果CIK细胞治疗组于CIK细胞治疗后2周,外周血CD3+、CD4+T细胞、NK细胞和CD4+/CD8+的比值、白细胞介素-2(IL-2)、干扰素γ(INF-γ)水平较治疗前升高(P<0.01),于治疗后4周达高峰,此后逐渐回落;而Th2细胞因子于CIK细胞治疗后2周下降,治疗后4周降至低谷。CIK细胞治疗组于CIK细胞治疗后2、4、8周CD3+、CD4+、CD4+/CD8+、NK细胞、IL-2、INF-γ、白细胞介素4(IL-4)和白细胞介素10(IL-10)与常规治疗组各时点比较差异有统计学意义[(P<0.05),治疗后4周CD3+70.2%±9.1%vs.46.3%±5.8%;CD4+40.2%±7.1%vs.22.9%±4.5%;CD4+/CD8+1.82±0.43vs.1.09±0.34;NK15.7%±5.4%vs.10.5%±2.5%;IL-234.8±11.7ng/Lvs.19.8±12.1ng/L;INF-γ63.7±23.3ng/Lvs.30.8±10.6ng/L;IL-410.2±8.6ng/Lvs.25.8±6.3ng/L;IL-1010.6±3.4ng/Lvs.21.4±8.6ng/L]。结论CIK细胞免疫治疗能增强NSCLC患者术后的免疫功能。

Objective To investigate the effect of cytokine-induced killer （CIK） cells immunotherapy on immunity function of non-small cell lung cancer （NSCLC） patients after operation. Methods Fifty patients with histological or cytological diagnosis of NSCLC on Ⅰ stage, Ⅱ stage and Ⅲa stage of tumor, nodes, metastasis- classification were randomly divided CIK cells therapy group and conventional therapy group, 25 cases each group. The immunity function of patients with NSCLC, including the levels of CD3＋ , CD4＋ T cells, ratio of CD4＋/CD8＋ , natural killer（NK） cells, and the levels of Th1/Th2 cytokine were detected before treatment, and the 2nd, 4th, 8th week after treatment. Results The levels of CD3＋, CD4＋ T cells, NK cells, ratio of CD4＋/CD8＋ , interleukin-2 （IL-2）, interferon-γ（INF-γ） in CIK cells therapy group at the 2nd week after treatment were more higher than those before treatment （P 〈0. 01）, their levels reached the peak at 4th week, from then on, it began to decrease. Meanwhile, the levels of Th2 of CIK cells therapy group began to decrease at the 2nd week after treatment, a low ebb at 4th week. At the 2nd, 4th and 8th week,the levels of CD3＋ ,CD4＋ T cells, ratio of CD4＋/CD8＋ , NK cells, IL-2, INF-γ, interleukin-4 （IL-4）, interleukin-10 （IL-10） of CIK cells therapy group compared with those in conventional therapy group, there were statistical significance difference [（P〈0.05）, at 4th week after treatment,CD3＋ 70. 2%±9. 1% vs. 46.3±5.8%; CD4＋40.2%±7.1% vs. 22.9%±4.5%; CD4＋/CD8＋ 1.82±0. 43 vs. 1.09±0.34; NK 15. 7%_＋5.4% vs. 10.5%±2.5%; IL-2 34.8±11.7 ng/L vs. 19.8±12. 1 ng/L; INF-γ63.7±23.3 ng/L vs. 30. 8±10. 6 ng/L; IL-4 10.2±8. 6 ng/L vs. 25.8±6.3 ng/L; IL-10 10.6±3.4 ng/L vs. 21.4±8. 6 ng/L]. Conclusion The results indicate that CIK cells immunotherapy can enhance the immune function of NSCLC patients after operation.